CD47 and ovarian carcinoma: It has shown remarkable anti-cancer efficacy across a variety of tumors, including colorectal cancer, lung cancer, osteosarcoma, ovarian cancer, and glioma (Jurgensen et al., 2021; Reid et al., 2022; Morgensztern et al., 2019; Das et al., 2016; Cottrill et al., 2018; Oronsky et al., 2021; Fang et al., 2022).The anti-cancer mechanisms of RRx-001 are varied and include inhibiting the CD47-SIRPαpathway, which repolarizes tumor-associated macrophages (TAM) from an anti-inflammatory M2 phenotype to a pro-inflammatory M1 phenotype.